Adherence to Levothyroxine Treatment Among Patients With Hypothyroidism in Madinah, Saudi Arabia: A Cross-Sectional Study.
drug adherence
hypothyroidism
levothyroxine
medication adherence
morisky medication adherence scale-8
saudi arabia
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
19
06
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Hypothyroidism is one of the most prevalent chronic diseases worldwide. The key factor for a good clinical outcome for hypothyroidism is medication adherence, as the mainstay treatment of hypothyroidism is lifelong hormonal replacement therapy, Levothyroxine (LT4). Poor adherence to LT4 is not only linked to great healthcare costs but also to significant economic burdens. The aim of this study is to assess the medication adherence of patients on LT4 treatment in the Madinah region and its association with socio-demographic characteristics, participants' experience with hypothyroidism and taking LT4, and Morisky Medication Adherence Scale 8-Item (MMAS-8). A cross-sectional study was conducted on 420 hypothyroidism patients on LT4 for at least three months in the Madinah region using a self-administered electronic form. The variables in the questionnaire included socio-demographic characteristics, participants' experience with hypothyroidism and taking LT4, and MMAS-8. This study included a total of 420 patients with 81% being females, 52.1% aged 40 years and above, and 91% living in Madinah City. The study shows an overall poor adherence rate toward taking LT4, where the vast majority, 66.7% of the participants, had a low adherence level toward taking LT4, 23.3% had a moderate adherence level, and only 10% had a high adherence level. Results of the multivariate logistic regression showed that the following factors predicted a higher rate of a high level of adherence toward taking levothyroxine, being 50-59 years old, being 60 years or older, and following up regularly in the clinic. Patients with hypothyroidism showed low adherence to LT4.
Sections du résumé
BACKGROUND
BACKGROUND
Hypothyroidism is one of the most prevalent chronic diseases worldwide. The key factor for a good clinical outcome for hypothyroidism is medication adherence, as the mainstay treatment of hypothyroidism is lifelong hormonal replacement therapy, Levothyroxine (LT4). Poor adherence to LT4 is not only linked to great healthcare costs but also to significant economic burdens.
OBJECTIVES
OBJECTIVE
The aim of this study is to assess the medication adherence of patients on LT4 treatment in the Madinah region and its association with socio-demographic characteristics, participants' experience with hypothyroidism and taking LT4, and Morisky Medication Adherence Scale 8-Item (MMAS-8).
METHODOLOGY
METHODS
A cross-sectional study was conducted on 420 hypothyroidism patients on LT4 for at least three months in the Madinah region using a self-administered electronic form. The variables in the questionnaire included socio-demographic characteristics, participants' experience with hypothyroidism and taking LT4, and MMAS-8.
RESULTS
RESULTS
This study included a total of 420 patients with 81% being females, 52.1% aged 40 years and above, and 91% living in Madinah City. The study shows an overall poor adherence rate toward taking LT4, where the vast majority, 66.7% of the participants, had a low adherence level toward taking LT4, 23.3% had a moderate adherence level, and only 10% had a high adherence level. Results of the multivariate logistic regression showed that the following factors predicted a higher rate of a high level of adherence toward taking levothyroxine, being 50-59 years old, being 60 years or older, and following up regularly in the clinic.
CONCLUSION
CONCLUSIONS
Patients with hypothyroidism showed low adherence to LT4.
Identifiants
pubmed: 37485132
doi: 10.7759/cureus.40686
pmc: PMC10358293
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e40686Informations de copyright
Copyright © 2023, Alofi et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Br J Gen Pract. 2005 May;55(514):362-8
pubmed: 15904555
Lancet. 2017 Sep 23;390(10101):1550-1562
pubmed: 28336049
Front Endocrinol (Lausanne). 2018 Nov 23;9:699
pubmed: 30532737
Pediatr Transplant. 2005 Jun;9(3):381-90
pubmed: 15910397
N Engl J Med. 2017 Aug 24;377(8):745-755
pubmed: 28834469
Pharmaceutics. 2021 Jul 20;13(7):
pubmed: 34371791
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Pharmacotherapy. 2008 Apr;28(4):437-43
pubmed: 18363527
N Engl J Med. 2017 Aug 24;377(8):733-744
pubmed: 28834483
Kathmandu Univ Med J (KUMJ). 2018 Apr-Jun;16(62):129-137
pubmed: 30636753
Cureus. 2019 May 8;11(5):e4624
pubmed: 31312550
East Mediterr Health J. 2019 Apr 25;25(3):149-159
pubmed: 31054225
Patient Prefer Adherence. 2020 Jul 06;14:1111-1117
pubmed: 32753851
PLoS One. 2014 Aug 14;9(8):e103090
pubmed: 25121589
East Mediterr Health J. 2015 Dec 13;21(10):722-8
pubmed: 26750162